Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 5827041, 9 pages
http://dx.doi.org/10.1155/2016/5827041
Research Article

A Comparison of hs-CRP Levels in New Diabetes Groups Diagnosed Based on FPG, 2-hPG, or HbA1c Criteria

1Division of Endocrinology & Metabolism, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, 34093 Istanbul, Turkey
2Department of Clinical Biochemistry, Istanbul Medical Faculty, Istanbul University, 34093 Istanbul, Turkey
3Department of Public Health, Istanbul Medical Faculty, Istanbul University, 34093 Istanbul, Turkey
4Centre for Vascular Prevention, Danube-University Krems, 3500 Krems, Austria
5Department of Chronic Disease Prevention, National Institute for Health and Welfare, 00271 Helsinki, Finland
6Diabetes Research Group, King Abdulaziz University, Jeddah 21589, Saudi Arabia

Received 3 July 2015; Revised 21 October 2015; Accepted 29 October 2015

Academic Editor: Francesco Chiarelli

Copyright © 2016 Yildiz Tutuncu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Pickup and M. A. Crook, “Is type II diabetes mellitus a disease of the innate immune system?” Diabetologia, vol. 41, no. 10, pp. 1241–1248, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Y. Donath and S. E. Shoelson, “Type 2 diabetes as an inflammatory disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 98–107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, “Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS),” Circulation, vol. 102, no. 1, pp. 42–47, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. P. M. Ridker, J. E. Buring, N. R. Cook, and N. Rifai, “C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women,” Circulation, vol. 107, no. 3, pp. 391–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, “Follow-up report on the diagnosis of diabetes mellitus,” Diabetes Care, vol. 26, no. 11, pp. 3160–3167, 2003. View at Google Scholar
  6. G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman, “IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance,” Science, vol. 271, no. 5249, pp. 665–668, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker, “C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus,” The Journal of the American Medical Association, vol. 286, no. 3, pp. 327–334, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. N. de Rekeneire, R. Peila, J. Ding et al., “Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition stud,” Diabetes Care, vol. 29, no. 8, pp. 1902–1908, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. I. Barzilay, L. Abraham, S. R. Heckbert et al., “The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health study,” Diabetes, vol. 50, no. 10, pp. 2384–2389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. D. J. Freeman, J. Norrie, M. J. Caslake et al., “C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland Coronary Prevention Study,” Diabetes, vol. 51, no. 5, pp. 1596–1600, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. I. Schmidt, B. B. Duncan, A. R. Sharrett et al., “Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study,” The Lancet, vol. 353, no. 9165, pp. 1649–1652, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. S. M. Haffner, L. Mykkänen, A. Festa, J. P. Burke, and M. P. Stern, “Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state,” Circulation, vol. 101, no. 9, pp. 975–980, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, “Report of the Expert Committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 21, no. supplement 1, pp. S5–S19, 1998. View at Publisher · View at Google Scholar
  14. The International Expert Committee, “International expert committee report on the role of the A1C assay in the diagnosis of diabetes,” Diabetes Care, vol. 32, no. 7, pp. 1327–1334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. World Health Organization, World Health Statistics 2011, WHO Press, Geneva, Switzerland, 2011.
  16. World Health Organization Europe, The European Health Report 2009: Health and Health Systems, WHO Regional Office for Europe, Copenhagen, Denmark, 2009.
  17. M. Speeckaert, W. Van Biesen, J. Delanghe et al., “Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?” Nephrology Dialysis Transplantation, vol. 29, no. 12, pp. 2167–2177, 2014. View at Publisher · View at Google Scholar
  18. Q. Qiao, K. Pyörälä, M. Pyörälä et al., “Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose,” European Heart Journal, vol. 23, no. 16, pp. 1267–1275, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Satman, B. Omer, Y. Tutuncu et al., “Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults,” European Journal of Epidemiology, vol. 28, no. 2, pp. 169–180, 2013. View at Publisher · View at Google Scholar
  20. National Kidney Foundation, “KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease,” Kidney International, vol. 3, no. 1, pp. 8–9, 2013. View at Google Scholar
  21. D. Aronson, P. Bartha, O. Zinder et al., “Association between fasting glucose and C-reactive protein in middle-aged subjects,” Diabetic Medicine, vol. 21, no. 1, pp. 39–44, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Fröhlich, A. Imhof, G. Berg et al., “Association between C-reactive protein and features of the metabolic syndrome: a population-based study,” Diabetes Care, vol. 23, no. 12, pp. 1835–1839, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Festa, R. D'Agostino Jr., R. P. Tracy, and S. M. Haffner, “Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study,” Diabetes, vol. 51, no. 4, pp. 1131–1137, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Rubio-Martín, F. Soriguer, C. Gutiérrez-Repiso et al., “C-reactive protein and incidence of type 2 diabetes in the Pizarra study,” European Journal of Clinical Investigation, vol. 43, no. 2, pp. 159–167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Wang, W. Bao, J. Liu et al., “Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis,” Diabetes Care, vol. 36, no. 1, pp. 166–175, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Festa, R. D'Agostino Jr., R. P. Tracy, and S. M. Haffner, “C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis study,” Diabetic Medicine, vol. 19, no. 11, pp. 939–943, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. C. C. Lee, A. I. Adler, M. S. Sandhu et al., “Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis,” Diabetologia, vol. 52, no. 6, pp. 1040–1047, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Lu, Y. Yang, Z. Yang et al., “Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity,” Cardiovascular Diabetology, vol. 9, article 92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men,” The New England Journal of Medicine, vol. 336, no. 14, pp. 973–979, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Fisher, M. Cushman, V. Knappertz, and G. Howard, “An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration,” American Heart Journal, vol. 156, no. 1, pp. 106–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. S. E. Kahn, B. Zinman, S. M. Haffner et al., “Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. ADOPT Study Group,” Diabetes, vol. 55, no. 8, pp. 2357–2364, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. A. D. Pradhan, J. E. Manson, J. E. Rossouw et al., “Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the women's health initiative observational study,” The Journal of the American Medical Association, vol. 288, no. 8, pp. 980–987, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Wu, J. P. Dorn, R. P. Donahue, C. T. Sempos, and M. Trevisan, “Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988–1994,” American Journal of Epidemiology, vol. 155, no. 1, pp. 65–71, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. A. G. Niehoff, T. W. van Haeften, N. C. Onland-Moret, C. C. Elbers, C. Wijmenga, and Y. T. Van Der Schouw, “C-reactive protein is independently associated with glucose but not with insulin resistance in healthy men,” Diabetes Care, vol. 30, no. 6, pp. 1627–1629, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Ilhan, Y. Tutuncu, S. Gedik et al., “Phenotypes and biochemical characteristics of new diabetes patients diagnosed based upon different criteria: HbA1c recognises people at a more advanced diabetic stage,” Diabetes, vol. 62, supplement 1, abstract A277, pp. S121–S122, 2013. View at Google Scholar
  36. C. den Engelsen, P. S. Koekkoek, K. J. Gorter, M. van den Donk, P. L. Salomé, and G. E. Rutten, “High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis,” Cardiovascular Diabetology, vol. 11, article 25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Oda, K. Oohara, A. Abe et al., “The optimal cut-off point of C-reactive protein as an optional component of metabolic syndrome in Japan,” Circulation Journal, vol. 70, no. 4, pp. 384–388, 2006. View at Publisher · View at Google Scholar · View at Scopus